Tecentriq CAS 1380723-44-3 Atezolizumab

Model: MOS-new6
Place of Origin: Zhejiang,China (Mainland)
Name: Tecentriq
Name 1: Atezolizumab
CAS: 1380723-44-3


skype basketAdd to Basket  Edit

Share |

Product Description

Payment & Shipping Terms Supply Capacity
Trade Term:FOB,CIF,DDPProduction Capacity:1kg/year
Payment Terms:T/T, WUPacking:according to the...
Min. Order:1 GramDelivery Date:7 days
Means of Transport:Ocean, Air, Land


CAS: 1380723-44-3

Pharmacological action and mechanism

Pd-l1 may be expressed on tumor cells and/or tumor infiltrated immune cells and may contribute to the inhibition of anti-tumor immune responses in tumor microenvironment. The binding of pd-l1 to T cells showed that pd-1 and B7.1 receptors and antigen presentation showed that the cells inhibited the activity of cytotoxic T cells, t-cell proliferation and cytokine production. Atjuzumab is a monoclonal antibody that binds to pd-l1 and blocks its interaction with pd-1 and B7.1 receptors. This release of pd-l1 / pd-1 mediated inhibition of immune responses, including activation of anti-tumor immune responses, does not induce antibody dependent cytotoxicity. In the homologous mouse tumor model, inhibition of pd-l1 activity leads to reduced tumor growth.

We can customize according to customer's requirement

if you have any question pls mail us or call us

Category: Hot anti-cancer medicines

Related Category: Pharmaceutical Intermediates  Customized Pharmaceutical API  Other Pharmaceutical API  Veterinary Medicine API  Diagnostic Agents API 

Offline Showroom in USA
QR Code